AMBER VASOLD: Open Payments
NPI 1013389683 · ABERDEEN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,289 in 65 payments from 13 companies in 2025. Trend: 2023 $2,260 · 2024 $1,822 · 2025 $1,289
Food & beverage: $1,289
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $265 |
| Amgen Inc. | 18 | $244 |
| AstraZeneca Pharmaceuticals LP | 8 | $164 |
| ABBVIE INC. | 8 | $138 |
| GlaxoSmithKline, LLC. | 5 | $95 |
| Lilly USA, LLC | 4 | $91 |
| PFIZER INC. | 4 | $80 |
| INTUITIVE SURGICAL, INC. | 1 | $77 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
Products named: OTEZLA, FARXIGA, EVENITY, Wegovy, TRELEGY ELLIPTA, MOUNJARO, Ozempic, Rybelsus.
Industry payments across MD — which companies pay providers there.
